Biological vulnerability for bipolar disorders (BD) in relatives of BD patients has not as yet been established. Serotonergic vulnerability was studied, using acute tryptophan depletion (ATD), in healthy first-degree relatives of BD patients and healthy controls. The effects of ATD on mood and cortisol release in 30 healthy adult, lifetime symptom free, unaffected first-degree relatives of BD patients (Family History; FH) were compared with effects in 15 healthy matched controls in a placebocontrolled, double-blind, crossover design. During ATD and placebo, salivary cortisol response was also assessed during a stress-inducing speech task (SIST). First-degree relatives of type II BD patients (FH II) showed an elevation of mood, whereas control subjects and relatives of type I BD patients (FH I) showed a lowering of mood after ATD. ATD was followed by a decrease in cortisol level in both FHIn the pathophysiology of bipolar disorders (BD), several lines of evidence support the hypothesis of an underlying dysfunction of the serotonergic system. Increased platelet serotonin (5-hydroxytryptamine or 5-HT), a lower maximal velocity (Vmax) of 5-HT platelet uptake and decreased central serotonergic neurotransmitter activity, indicated by decreased 5HIAA/5-HT ratios, have been reported in untreated bipolar depressed patients (Wirz Justice and Puhringer 1978; Marazziti et al.1991;Leake et al. 1991;Young et al. 1994). Polymorphism in the 5-HT-transporter, 5-HT receptors and the tryptophan hydroxylase gene have been associated with the pathophysiology of BD (Kunugi et al. 1997;Oruc et al. 1997;Bellivier et al. 1998).Acute tryptophan depletion (ATD) is a direct method to investigate central serotonergic vulnerability (Delgado et al. 1994). In this procedure, a lowering of central
5-HT Vulnerability in Relatives of Bipolar Patients 8355-HT synthesis is accomplished by giving subjects a 50-100 g balanced amino acid-drink (AA-drink), composed of amino acids, including large neutral amino acids (LNAAs: tyrosine, valine, leucine, isoleucine and phenylalanine), and devoid of tryptophan (Trp) (Young 1991). In remitted depressed patients, ATD induced depressive symptoms (Smith et al. 1997;Aberg-Wistedt et al. 1998;Moreno et al. 2000). In healthy first-degree relatives of depressed patients, ATD induced a modest lowering of mood, compared with healthy control subjects (Benkelfat et al. 1994;Klaassen et al. 1999). It thus appears that individuals without prior depressive episodes, but at a genetic risk for depression, may be biologically predisposed to mood-lowering effects of ATD.Until now, little attention has been paid to the effects of ATD in BD, and results are inconsistent . Cappiello et al. (1997) reported a significant increase in manic symptoms in recently remitted (one month) lithium-treated manic patients. In BD patients who were stable for a longer period (1-15 years), ATD did not induce significant mood changes (Benkelfat et al. 1995;Cassidy et al. 1998;Hughes et al. 2000).In BD patients abnormalities in cortisol homeostas...